Press release
Congestive Heart Failure Market Poised for Substantial Growth by 2034: Recent FDA Approvals, Strategic Market Opportunities | DelveInsight
Congestive Heart Failure Market
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast- 2034 [https://www.delveinsight.com/report-store/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into congestive heart failure, historical and forecasted epidemiology, and market trends across the seven major heart failure major markets, which include the US, EU4 countries (Germany, France, Italy, and Spain), the UK, and Japan. According to the analysis, the total chronic heart failure market size in the 7MM was approximately USD 7 billion and is projected to grow significantly during the forecast period (2024-2034).
The US accounts for the largest market share of the total congestive heart failure market size and will continue to experience substantial growth throughout the forecast period. Among the EU4 and the UK, Germany contributes the highest revenue share, while the UK has the smallest market share. This regional disparity is attributed to varying prevalence rates, healthcare infrastructure differences, and reimbursement policies across markets.
Download the Congestive Heart Failure Market Forecast Report to understand which factors are driving the congestive heart failure market @ Congestive Heart Failure Market Trends [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
From the epidemiological perspective, the total congestive heart failure patient pool in the 7MM was approximately 21 million in 2023, with males representing a higher share compared to females. Furthermore, the majority of heart failure cases occur in individuals aged 60 years and above. In 2023, this age group accounted for approximately 7 million heart failure cases in the US.
DelveInsight's analysis segments this patient population by various parameters, including total diagnosed prevalent cases, gender-specific cases, age-specific cases, NYHA class-specific cases, ejection fraction-specific cases, and type-specific cases (acute and chronic). Heart failure with preserved ejection fraction (HFpEF) contributes to the majority of cases, while NYHA class II and class III represent the highest proportion among class-specific diagnosed prevalence.
Discover evolving trends in the congestive heart failure patient pool forecasts @Congestive Heart Failure Epidemiological Analysis [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The DelveInsight report also analyses the congestive heart failure drugs market and treatment landscape. The current congestive heart failure treatment landscape relies heavily on established drug classes like ACE inhibitors, ARBs, beta-blockers, and diuretics. Among the approved therapies, ENTRESTO (sacubitril/valsartan) from Novartis (SWX: NOVN) leads the market and is expected to maintain its dominant position during the forecast period, followed by beta blockers. However, with Novartis expecting to lose exclusivity in the United States in 2025, the introduction of generics poses a significant threat to this billion-dollar medication.
SGLT2 inhibitors such as JARDIANCE (empagliflozin) from Boehringer Ingelheim and Eli Lilly (NYSE: LLY), and FARXIGA (dapagliflozin) from AstraZeneca (LON: AZN) have gained substantial traction in the congestive heart failure therapeutic landscape. In June 2021, the European Commission granted marketing authorization for JARDIANCE as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction, followed by FDA approval in August 2021.
In March 2025, the FDA approved AMVUTTRA, an RNA interference therapy manufactured by Alnylam Pharmaceuticals (NASDAQ: ALNY), for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare but serious cause of heart failure, marking the first RNAi drug to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in this population.
Furthermore, in December 2024, the FDA granted tentative approval to SQ Innovation's Lasix ONYU, a combination of a high-concentration furosemide formulation and an on-body drug delivery device developed by Gerresheimer, for home treatment of fluid overload in congestive heart failure. Full approval is expected after a competing product's exclusivity ends in October 2025, with market launch anticipated by the end of 2025.
The congestive heart failure pipeline is robust, with several promising candidates in various stages of clinical development. In December 2024, AstraZeneca initiated a Phase IIb randomized, placebo-controlled study evaluating AZD5462 in stable patients with chronic heart failure. Similarly, Regeneron Pharmaceuticals began investigating REGN5381, an NPR1 monoclonal antibody agonist, in patients with chronic heart failure with reduced ejection fraction. Other notable pipeline drugs include KERENDIA (Bayer), MOUNJARO (Eli Lilly), Semaglutide (Novo Nordisk), CardiAMP Cell Therapy (BioCardia), and Mesoblast.
The use of stem cells to stimulate myocardial healing represents a promising new approach to treating heart failure. The late-stage cell therapy CardiAMP Cell Therapy by BioCardia (NASDAQ: BCDA) is expected to secure a significant market position, highlighting the growing interest in regenerative medicine approaches for cardiovascular conditions.
Several notable developments have occurred recently in the treatment landscape for congestive heart failure. In late April 2025, new clinical trial data presented at Heart Rhythm 2025 highlighted that left bundle branch area pacing (LBBAP) offers better outcomes than traditional biventricular pacing for patients needing cardiac resynchronization, reducing death and heart failure hospitalizations. Additionally, in March 2025, the FDA granted priority review to KERENDIA for heart failure with preserved ejection fraction, with a decision expected in the third quarter of 2025.
Discover evolving trends in the congestive heart failure treatment landscape @ Congestive Heart Failure Recent Developments [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite these advancements, significant challenges remain in the congestive heart failure market. The high price of recently developed therapies, general reluctance of cardiologists to adopt new treatment options, and widespread use of generic heart failure drugs make it difficult for premium-priced branded therapies to penetrate the market effectively. Additionally, the chronic heart failure market faces challenges from underdiagnosis and delayed recognition due to overlapping symptoms with other conditions.
Looking forward, the chronic heart failure market is poised for substantial growth, driven by the anticipated expanded indication for therapies like Bayer's KERENDIA, the launch of several oral and injectable agents, and the increasing global prevalence of chronic heart failure, potentially reshaping the treatment landscape in the coming years.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Congestive Heart Failure
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Congestive Heart Failure (CHF) Market Overview At A Glance
7. Disease Background and Overview
8. Congestive Heart Failure Treatment
9. Heart Failure with Preserved Ejection Fraction: Diagnosis And Management
10. Congestive Heart Failure Guidelines
11. Congestive Heart Failure Epidemiology and Patient Population
12. Congestive Heart Failure Patient Journey
13. Congestive Heart Failure Marketed Drugs
14. Congestive Heart Failure Emerging Drugs
15. Congestive Heart Failure (CHF): 7MM Analysis
16. Congestive Heart Failure Unmet Needs
17. Swot Analysis
18. Kol Views
19. Market Access and Reimbursement
20. Appendix
21. Delveinsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=congestive-heart-failure-market-poised-for-substantial-growth-by-2034-recent-fda-approvals-strategic-market-opportunities-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Congestive Heart Failure Market Poised for Substantial Growth by 2034: Recent FDA Approvals, Strategic Market Opportunities | DelveInsight here
News-ID: 4214641 • Views: …
More Releases from ABNewswire
The Silver Clover & Co. Redefines Anniversary Gifting Through Personalized Jewel …
Jewelry retailer addresses common gift-giving anxiety by pairing timeless pieces with message cards that help express emotions words alone cannot capture.
The jewelry retail landscape welcomes a thoughtful innovation as The Silver Clover & Co. addresses a universal challenge faced by anniversary gift-givers: how to convey the depth of years spent together through a single present. Through its unique combination of carefully curated jewelry, personalized message cards, and luxury presentation packaging,…
Diabetic Macular Edema Pipeline 2025: Innovative Clinical Developments by 45+ Gl …
Diabetic Macular Edemacompanies are Unity Biotechnology, Therini Bio, Valo Health, Kyowa Kirin, Invirsa, Frontera Therapeutics, EyePoint Pharmaceuticals, EyeBiotech, EnnovaBio, Eclipse Life Sciences, Merck, Rezolute, Aviceda Therapeutics, KODIAK SCIENCES, AsclepiX Therapeutics, and others.
As Diabetic Macular Edema (DME) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising demand for safer and more effective treatment options. DelveInsight reports that more than 45…
Royal Window Treatments Expands Window Upholstery in New York Services with Enha …
Royal Window Treatments celebrates 20 years of serving Manhattan by expanding its Hunter Douglas products, offering motorized shades, custom blinds, and expert installation for NYC homes and offices.
After more than two decades of serving Manhattan residents, Royal Window Treatments [https://www.google.com/maps/place/Royal+Window+Treatments/@40.736962,-73.9847553,683m/data=!3m2!1e3!4b1!4m6!3m5!1s0x89c25909f3cf88eb:0x1f91d68f43f25072!8m2!3d40.736962!4d-73.9847553!16s%2Fg%2F1tvm3pcf!5m1!1e1?entry=ttu&g_ep=EgoyMDI1MTAxNC4wIKXMDSoASAFQAw%3D%3D] announces an expanded selection of premium window covering solutions, including an extensive collection of Hunter Douglas products. The Midtown Manhattan-based company continues to address the unique challenges faced by New…
Triad Electric Solutions Adopts Advanced Thermal Imaging Technology to Reduce El …
Triad Electric Solutions implements thermal imaging technology, reducing electrical diagnostic time by 50% while improving safety and accuracy for customers throughout the North Carolina Triad region.
Local electrical contractor Triad Electric Solutions has implemented state-of-the-art thermal imaging technology across its operations, significantly improving diagnostic capabilities and reducing service call duration. The Greensboro-based company, led by owner David Angel, reports that the new technology has cut electrical repair [https://maps.google.com/maps?ll=36.116673,-79.783811&z=16&t=m&hl=en&gl=PH&mapclient=embed&cid=8975902741359798768&q=electrical+repair&oq=electrician+near+me] diagnostic time in…
More Releases for Heart
Heart Healthy Foods and Supplements vs Heart Conditions
Heart conditions remain a major health concern worldwide, but the good news is that specific heart healthy foods and supplements can significantly improve cardiovascular health.
Scientific research has demonstrated that certain foods, nutrients and supplements support heart function, reduce inflammation, and lower the risk of heart disease.
Top Heart Healthy Foods
Fatty Fish - Salmon, mackerel, and sardines are rich in omega-3 fatty acids, which help lower blood pressure and reduce inflammation. A…
Centrifugal Heart Pumps Market | Abbott Laboratories, Abiomed, Berlin Heart, Car …
The global centrifugal heart pumps market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the centrifugal heart pumps market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr
When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue…
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH…
HEART PUMP DEVICES Market 2020 | SWOT Analysis By Top Players Abbott Laboratorie …
A detailed study on HEART PUMP DEVICES Market formulated by Brandessence Market Research, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant information pertaining to the industry's size, share, application, and statistics are also summed in the report in order to present an ensemble prediction. In addition, this report undertakes an accurate competitive analysis illustrating the status of market majors in…
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot
Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after…
